ArticleThe Journal of biological chemistry2012
Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 146 citations in OpenAlex.
- Derivation of Equine Mesenchymal Stem/Stromal Cells from Induced Pluripotent Stem Cells via the Neural Crest Pathway and Characterisation by Immunophenotype and Tri-Lineage Differentiation.Animals : an open access journal from MDPI · 2026Article
- Optimizing Primary Human Salivary Stem/Progenitor Cells for Tissue Engineering Applications.bioRxiv : the preprint server for biology · 2026Article
- The Broken Cradle: Bone Marrow Stem Cell Niche Remodelling in Diabetes.Stem cell reviews and reports · 2026Review
- Tissue-engineered dermal substitutes constructed by human embryonic stem cell-derived fibroblasts facilitate the repair of skin wounds.Frontiers in bioengineering and biotechnology · 2026Article
- Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy.Stem cell reviews and reports · 2026Review
- Article
- State-of the-art and future perspective in co-culture systems for tendon engineering.Biomaterials and biosystems · 2025Article
- Unveiling heterogeneity in MSCs: exploring marker-based strategies for defining MSC subpopulations.Journal of translational medicine · 2024Review
- Quality Control of Stem Cell-Based Cultured Meat According to Specific Differentiation Abilities.Cells · 2024Article
- Expression of Concern: Characterization of Stem-Like Cells in Mucoepidermoid Tracheal Paediatric Tumor.PloS one · 2024Article
- The functional and molecular impact of triamcinolone acetonide on primary human bone marrow mesenchymal stem cells.Scientific reports · 2023Article
- Skin mesenchymal niches maintain and protect AML-initiating stem cells.The Journal of experimental medicine · 2023Article
- Article
- New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24- non-hematopoietic rare cell phenotype with breast cancer residual disease.Journal of cancer research and clinical oncology · 2023Article
- Development and clinical application of human mesenchymal stem cell drugs.Science bulletin · 2023Article
- Mesenchymal/stromal stem cells: necessary factors in tumour progression.Cell death discovery · 2022Review
- The secretion profile of mesenchymal stem cells and potential applications in treating human diseases.Signal transduction and targeted therapy · 2022Review
- Reversible switching of leukemic cells to a drug-resistant, stem-like subset via IL-4-mediated cross-talk with mesenchymal stroma.Haematologica · 2022Article
- Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche.Frontiers in oncology · 2022Review
- Inflammatory stromal cells in the myeloma microenvironment.Nature immunology · 2021Article
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant progress in our understanding of mesenchymal stem cell (MSC) biology during recent years, much of the information is based on experiments using in vitro culture-selected stromal progenitor cells. Therefore, the natural cellular identity of MSCs remains poorly defined. Numerous studies have reported that CD44 expression is one of the characteristics of MSCs in both humans and mice; however, we here have prospectively isolated bone marrow stromal cell subsets from both human and mouse bone marrow by flow cytometry and characterized them by gene expression analysis and function assays. Our data provide functional and molecular evidence suggesting that primary mesenchymal stem and progenitor cells of bone marrow reside in the CD44(-) cell fraction in both mice and humans. The finding that these CD44(-) cells acquire CD44 expression after in vitro culture provides an explanation for the previous misconceptions concerning CD44 expression on MSCs. In addition, the other previous reported MSC markers, including CD73, CD146, CD271, and CD106/VCAM1, are also differentially expressed on those two cell types. Our microarray data revealed a distinct gene expression profile of the freshly isolated CD44(-) cells and the cultured MSCs generated from these cells. Thus, we conclude that bone marrow MSCs physiologically lack expression of CD44, highlighting the natural phenotype of MSCs and opening new possibilities to prospectively isolate MSCs from the bone marrow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.